Infliximab Treatment for Refractory Kawasaki Disease in Korean Children
![]() |
Song, Min-Seob
(Department of Pediatrics, Paik Hospital, College of Medicine, Inje University)
Lee, Sang-Bum (Department of Pediatrics, College of Medicine, Kyungpook National University) Sohn, Se-Jung (Department of Pediatrics, Mokdong Hospital, College of Medicine, Ewha Womans University) Oh, Jin-Hee (Department of Pediatrics, St.Vincent's Hospital, College of Medicine, The Catholic University of Korea) Yoon, Kyung-Lim (Department of Pediatrics, Eastwest Neo Medical Center, College of Medicine, Kyung Hee University) Han, Ji-Whan (Department of Pediatrics, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea) Kim, Chul-Ho (Department of Pediatrics, Paik Hospital, College of Medicine, Inje University) |
1 | Lahdenne P, Vahasalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 2003;62:245-7. DOI ScienceOn |
2 | Baldassano R, Braegger CP, Escher JC, et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 2003;98:833-8. DOI ScienceOn |
3 | Hirono K, Kemmotsu Y, Wittkowski H, et al. Infliximab reduces the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory Kawasaki disease. Pediatr Res 2009;65:696-701. DOI ScienceOn |
4 | Hui-Yuen JS, Duong TT, Yeung RS. TNF-alpha is necessary for induction of coronary artery inflammation and aneurysm formation in an animal model of Kawasaki disease. J Immunol 2006;176:6294-301. |
5 | Nachiappan J, May M, Hawker RE, Hong P. Resistant Kawasaki disease. J Paediatr Child Health 2004;40:576-8. DOI ScienceOn |
6 | Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006;113:2606-12. DOI ScienceOn |
7 | Fukunishi M, Kikkawa M, Hamana K, et al. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset. J Pediatr 2000;137:172-6. DOI ScienceOn |
8 | Muta H, Ishii M, Egami K, et al. Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan. J Pediatr 2004;144:496-9. DOI ScienceOn |
9 | Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979;63:175-9. |
10 | Wright DA, Newburger JW, Baker A, Sumdel RP. Treatment of immune- globulin resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996;128:146-9. DOI ScienceOn |
11 | Miura M, Ohki H, Yoshiba S, et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Arch Dis Child 2005;90:1096-7. DOI ScienceOn |
12 | Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C. Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol 2003;24:145-8. DOI ScienceOn |
13 | Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child 2008;93:142-6. DOI ScienceOn |
14 | Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324:1633-9. DOI ScienceOn |
15 | Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. Pediatr Infect Dis J 1998;17:1144-8. DOI ScienceOn |
16 | Lang BA, Yeung RS, Oen KG, et al. Corticosteroid treatment of refractory Kawasaki disease. J Rheumatol 2006;33:803-9. |
17 | Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005;146:662-7. DOI ScienceOn |
18 | Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004;110:2747-71. DOI ScienceOn |
19 | Weiss JE, Eberhard A, Chowdhury D, Gottlieb BS. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 2004;31: 808-10. |
20 | Research Committee on Kawasaki Disease. Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease. Tokyo, Japan: Ministry of Health and Welfare; 1984. |
21 | Sundel RP, Burns JC, Baker A, Beiser AS, Newburger JW. Gamma globulin re-treatment in Kawasaki disease. J Pediatr 1993;123:657-9. DOI ScienceOn |
22 | Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104. DOI ScienceOn |
23 | Burns JC, Glode MP. Kawasaki syndrome. Lancet 2004;364:533-44. DOI ScienceOn |
24 | Freeman AF, Shulman ST. Refractory Kawasaki disease. Pediatr Infect Dis J 2004;23:463-4. DOI ScienceOn |
25 | Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974;54:271-6. |
26 | Kato H, Sugimura T, Akagi T, et al. Long-term consequences of Kawasaki disease: a 10- to 21-year follow-up study of 594 patients. Circulation 1996;94:1379-85. DOI ScienceOn |
27 | Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315:341-7. DOI ScienceOn |
28 | Shin JU, Cho HK, Shin MS. Elevated tumor necrosis factor-alpha in stable angina pectoris. Korean Circ J 2000;30:861-6. |
29 | Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 2003;17:75-84. |
30 | Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265-7. DOI ScienceOn |
![]() |